Literature DB >> 17955730

Treatment strategies for C. difficile associated diarrhea.

Crenguta Stepan1, Christina M Surawicz.   

Abstract

Clostridium difficile-associated diarrhea usually occurs as a complication of antibiotic treatment. Recent data shows an increase in incidence rate of CDAD and higher rates of morbidity, colectomy and death. The management of CDAD involves discontinuing the inciting antibiotic agent and treatment with metronidazole or vancomycin. The reduced response rates and higher recurrence rates with metronidazole treatment reported in recent studies raise the question of the effectiveness of metronidazole therapy. After each recurrence, the risks for further relapses grow even bigger (after two recurrences, the risk being greater than 50%) and the management of recurrent CDAD becomes a challenge. Even after a careful review of available data on various drugs and having the experience of managing many cases of CDAD, one might find difficult to present with a successful "recipe" for treating severe CDAD. Every case is different and different management plans can lead to full recovery. First episode are metronidazole. If there is no improvement in three days or white blood cell count is more than 12,000 or creatinine level is high, metronidazole should be discontinued and vancomycin should be started. The latest trend of CDAD with more severe cases and increasing morbidity and mortality may be an incentive for using vancomycin as first line in some ases for RCDAD. Adding S boulardii to vancomycin or metronidazole from the first or second relapse and using pulse/tapering vancomycin therapy have been beneficial in decreasing the relapse rate. For patients with RCDAD, vancomycin therapy followed by rifaximin for two weeks looks promising. New therapies with, nitazoxanide, tinidazole, tiacumicin, rifaximin and ramoplanin are being evaluated and future reports and trials will show their efficacy. Immune therapy is also a promising option treatment in evaluation, showing seroconversion and protective antibody levels in initial tests in healthy volunteer. Passive immunization is also considered but for all these new therapy options, further randomized studies are needed. Prevention is also very important in controlling this disease: first by limiting the use of broad spectrum antibiotics and secondly by controlling the environmental spreading through gloves, handwashing and disposable thermometers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17955730

Source DB:  PubMed          Journal:  Acta Gastroenterol Latinoam        ISSN: 0300-9033


  4 in total

1.  [Recurrent Clostridium difficile infection. Treatment with duodenal infusion of donor feces].

Authors:  T Seufferlein; A Kleger; S Nitschmann
Journal:  Internist (Berl)       Date:  2014-04       Impact factor: 0.743

2.  Fecal transplant in refractory Clostridium difficile colitis.

Authors:  Alexander Kleger; Jacqueline Schnell; Andreas Essig; Martin Wagner; Martin Bommer; Thomas Seufferlein; Georg Härter
Journal:  Dtsch Arztebl Int       Date:  2013-02-15       Impact factor: 5.594

3.  Guidelines for the treatment of bacterial vaginosis: focus on tinidazole.

Authors:  Laura J Dickey; Michael D Nailor; Jack D Sobel
Journal:  Ther Clin Risk Manag       Date:  2009-07-12       Impact factor: 2.423

4.  A rare case intractable diarrhea secondary to Clostridium difficile and cytomegalovirus coinfection.

Authors:  Santhosh Gheevarghese John; Cristian Dominguez; Vijay Chandiramani; Tejo Vemulappalli
Journal:  Am J Case Rep       Date:  2013-11-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.